Vaginal atrophy in breast cancer survivors: Role of vaginal estrogen therapy

Gynecological Endocrinology

Volumn 29, Issue 1, 2013, Pages 25-29

  Mariani, Luciano ^a   Gadducci, Angiolo ^b   Vizza, Enrico ^a   Tomao, Silverio ^c   Vici, Patrizia ^a  

^a REGINA ELENA NATIONAL CANCER INSTITUTE   (Italy)

^b UNIVERSITY OF PISA   (Italy)

^c SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

Breast cancer survivors; Menopause treatment related; Tamoxifen and aromatase inhibitors therapy; Vaginal estrogen therapy

Indexed keywords

ANASTROZOLE; CONJUGATED ESTROGEN; ESTRADIOL; ESTRIOL; ESTROGEN; EXEMESTANE; LETROZOLE; PLACEBO; TAMOXIFEN;

ARTICLE; BREAST CANCER; CANCER SURVIVOR; CLINICAL ASSESSMENT; CREAM; DRUG BLOOD LEVEL; DRUG CONTRAINDICATION; DRUG DOSAGE FORM COMPARISON; DYSPAREUNIA; ESTROGEN THERAPY; HOT FLUSH; HUMAN; MENOPAUSE; PATHOGENESIS; PRIORITY JOURNAL; RISK BENEFIT ANALYSIS; TABLET; VAGINA ATROPHY; VAGINA PESSARY; VAGINAL DRYNESS;

ADMINISTRATION, INTRAVAGINAL; ANTINEOPLASTIC AGENTS, HORMONAL; AROMATASE INHIBITORS; ATROPHY; BREAST NEOPLASMS; ESTRIOL; ESTROGENS; FEMALE; HUMANS; NEOPLASM RECURRENCE, LOCAL; RISK FACTORS; SURVIVORS; TAMOXIFEN; VAGINA; VAGINAL DISEASES;

EID: 84870491284     PISSN: 09513590     EISSN: 14730766     Source Type: Journal    
DOI: 10.3109/09513590.2012.705389     Document Type: Article

References (56)

1. Joslyn SA. Hormone receptors in breast cancer: racial differences in distribution and survival. Breast Cancer Res Treat 2002;73:45-59.
2. National Cancer Institute. Surveillance Epidemiology and End Results Web site. SEER stat fact sheets: breast. Available at: http://seer.cancer. gov/statfacts/html /breast.html. Accessed January 19, 2011.
3. Basson R, Berman J, Burnett A, Derogatis L, Ferguson D, Fourcroy J, Goldstein I, et al. Report of the international consensus development conference on female sexual dysfunction: definitions and classifications. J Urol 2000;163:888-893.
4. Ganz PA, Rowland JH, Meyerowitz BE, Desmond KA. Impact of different adjuvant therapy strategies on quality of life in breast cancer survivors. Recent Results Cancer Res 1998;152:396-411.
5. Cella D, Fallowfield L, Barker P, Cuzick J, Locker G, Howell A; ATAC Trialistsa9 Group. Quality of life of postmenopausal women in the ATAC ("Arimidex", tamoxifen, alone or in combination) trial after completion of 5 years' adjuvant treatment for early breast cancer. Breast Cancer Res Treat 2006;100:273-284.
6. Fallowfield L, Cella D, Cuzick J, Francis S, Locker G, Howell A. Quality of life of postmenopausal women in the Arimidex, Tamoxifen, Alone or in Combination (ATAC) Adjuvant Breast Cancer Trial. J Clin Oncol 2004;22:4261-4271.
7. Hershman DL, Shao T, Kushi LH, Buono D, Tsai WY, Fehrenbacher L, Kwan M, et al. Early discontinuation and non-adherence to adjuvant hormonal therapy are associated with increased mortality in women with breast cancer. Breast Cancer Res Treat 2011;126:529-537.
8. Fellowes D, Fallowfield LJ, Saunders CM, Houghton J. Tolerability of hormone therapies for breast cancer: how informative are documented symptom profiles in medical notes for 'well-tolerated' treatments? Breast Cancer Res Treat 2001;66:73-81.
9. Burwell SR, Case LD, Kaelin C, Avis NE. Sexual problems in younger women after breast cancer surgery. J Clin Oncol 2006;24:2815-2821.
10. Hewitt OM. From cancer patient to cancer survivor: lost in transition. In: Hewitt M, Greenfield S, Stovall E, editors. Washington, DC: The National Academies Press; 2006.
11. James A. Simon identifying and treating sexual dysfunction in postmenopausal women: the role of estrogen. J Womens Health 2011;20:1453-1465.
12. Nelson HD, Vesco KK, Haney E, Fu R, Nedrow A, Miller J, Nicolaidis C, et al. Nonhormonal therapies for menopausal hot flashes: systematic review and meta-analysis. JAMA 2006;295:2057-2071.
13. Pandya KJ, Morrow GR, Roscoe JA, Zhao H, Hickok JT, Pajon E, Sweeney TJ, et al. Gabapentin for hot flashes in 420 women with breast cancer: a randomised double-blind placebo-controlled trial. Lancet 2005;366:818-824.
14. Nachtigall LE. Comparative study: replens versus local estrogen in menopausal women. Fertil Steril 1994;6:1178-1180.
15. Gupta P, Sturdee DW, Palin SL, Majumder K, Fear R, Marshall T, Paterson I. Menopausal symptoms in women treated for breast cancer: the prevalence and severity of symptoms and their perceived effects on quality of life. Climacteric 2006;9:49-58.
16. Nelson H, Haney E, Humphrey L, Miller J, Nedrow A, Nocolaidis C, Vesco K, et al. Management of menopause-related symptoms. Evidence report/technology assessment 120. Rockville, MD: Agency for Healthcare Research and Quality; 2005.
17. Bachmann GA, Leiblum SR. The impact of hormones on menopausal sexuality: a literature review. Menopause 2004;11:120-130.
18. Santoro N, Komi J. Prevalence and impact of vaginal symptoms among postmenopausal women. J Sex Med 2009;6:2133-2142.
19. Ottesen B, Pedersen B, Nielsen J, Dalgaard D, Wagner G, Fahrenkrug J. Vasoactive intestinal polypeptide (VIP) provokes vaginal lubrication in normal women. Peptides 1987;8:797-800.
20. Bradshaw HB, Berkley KJ. Estrogen replacement reverses ovariectomyinduced vaginal hyperalgesia in the rat. Maturitas 2002;41:157-165.
21. Harris PF, Remington PL, Trentham-Dietz A, Allen CI, Newcomb PA. Prevalence and treatment of menopausal symptoms among breast cancer survivors. J Pain Symptom Manage 2002;23:501-509.
22. Brueggemeier RW, Hackett JC, Diaz-Cruz ES. Aromatase inhibitors in the treatment of breast cancer. Endocr Rev 2005;26:331-345.
23. Cardozo L, Bachmann G, McClish D, Fonda D, Birgerson L. Metaanalysis of estrogen therapy in the management of urogenital atrophy in postmenopausal women: second report of the Hormones and Urogenital Therapy Committee. Obstet Gynecol 1998;92:722-727.
24. Suckling J, Lethaby A, Kennedy R. Local oestrogen for vaginal atrophy in postmenopausal women. Cochrane Database Syst Rev 2003;4:CD001500.
25. Dorr MB, Nelson AL, Mayer PR, Ranganath RP, Norris PM, Helzner EC, Preston RA. Plasma estrogen concentrations after oral and vaginal estrogen administration in women with atrophic vaginitis. Fertil Steril 2010;94:2365-2368.
26. Long CY, Liu CM, Hsu SC, Wu CH, Wang CL, Tsai EM. A randomized comparative study of the effects of oral and topical estrogen therapy on the vaginal vascularization and sexual function in hysterectomized postmenopausal women. Menopause 2006;13:737-743.
27. Sturdee DW and Pines A on behalf of the International Menopause Society Writing Group. IMS recommendations on postmenopausal hormone therapy and preventive strategies for midlife health. Climateric 2011;14:302-320.
28. Weisberg E, Ayton R, Darling G, Farrell E, Murkies A, O'Neill S, Kirkegard Y, Fraser IS. Endometrial and vaginal effects of low-dose estradiol delivered by vaginal ring or vaginal tablet. Climacteric 2005;8:83-92.
29. Simon J, Nachtigall L, Gut R, Lang E, Archer DF, Utian W. Effective treatment of vaginal atrophy with an ultra-low-dose estradiol vaginal tablet. Obstet Gynecol 2008;112:1053-1060.
30. Rosenberg LU, Magnusson C, Lindström E, Wedrén S, Hall P, Dickman PW. Menopausal hormone therapy and other breast cancer risk factors in relation to the risk of different histological subtypes of breast cancer: a case-control study. Breast Cancer Res 2006;8:R11.
31. Goss PE, Ingle JN, Martino S, Robert NJ, Muss HB, Piccart MJ, Castiglione M, et al. A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer. N Engl J Med 2003;349:1793-1802.
32. Moegele M, Buchholz S, Seitz S, Ortmann O. Vaginal estrogen therapy in postmenopausal breast cancer patients treated with aromatase inhibitors. Arch Gynecol Obstet 2012;285:1397-1402.
33. Pruthi S, Simon JA, Early AP. Current overview of the management of urogenital atrophy in women with breast cancer. Breast J 2011;17:403-408.
34. Nilsson K, Heimer G. Low-dose oestradiol in the treatment of urogenital oestrogen deficiency-a pharmacokinetic and pharmacodynamic study. Maturitas 1992;15:121-127.
35. Santen RJ, Allred DC, Ardoin SP, Archer DF, Boyd N, Braunstein GD, Burger HG, et al.; Endocrine Society. Postmenopausal hormone therapy: an Endocrine Society scientific statement. J Clin Endocrinol Metab 2010;95:s1-s66.
36. Al-Baghdadi O, Ewies AA. Topical estrogen therapy in the management of postmenopausal vaginal atrophy: an up-to-date overview. Climacteric 2009;12:91-105.
37. Dugal R, Hesla K, Sørdal T, Aase KH, Lilleeidet O, Wickstrøm E. Comparison of usefulness of estradiol vaginal tablets and estriol vagitories for treatment of vaginal atrophy. Acta Obstet Gynecol Scand 2000;79:293-297.
38. The 2012 hormone therapy position statement of: The North American Menopause Society. Menopause 2012;19:257-271.
39. Labrie F, Cusan L, Gomez JL, Côté I, Bérubé R, Bélanger P, Martel C, Labrie C. Effect of one-week treatment with vaginal estrogen preparations on serum estrogen levels in postmenopausal women. Menopause 2009;16:30-36.
40. Dew JE, Wren BG, Eden JA. A cohort study of topical vaginal estrogen therapy in women previously treated for breast cancer. Climacteric 2003;6:45-52.
41. Vassilopoulou-Sellin R, Theriault R, Klein MJ. Estrogen replacement therapy in women with prior diagnosis and treatment for breast cancer. Gynecol Oncol 1997; 65:89-93.
42. Ponzone R, Biglia N, Jacomuzzi ME, Maggiorotto F, Mariani L, Sismondi P. Vaginal oestrogen therapy after breast cancer: is it safe? Eur J Cancer 2005;41:2673-2681.
43. Hickey M, Saunders C, Partridge A, Santoro N, Joffe H, Stearns V. Practical clinical guidelines for assessing and managing menopausal symptoms after breast cancer. Ann Oncol 2008;19:1669-1680.
44. Kendall A, Dowsett M, Folkerd E, Smith I. Caution: Vaginal estradiol appears to be contraindicated in postmenopausal women on adjuvant aromatase inhibitors. Ann Oncol 2006;17:584-587.
45. Biglia N, Peano E, Sgandurra P, Moggio G, Panuccio E, Migliardi M, Ravarino N, et al. Low-dose vaginal estrogens or vaginal moisturizer in breast cancer survivors with urogenital atrophy: a preliminary study. Gynecol Endocrinol 2010;26:404-412.
46. Sturdee DW, Panay N; International Menopause Society Writing Group. Recommendations for the management of postmenopausal vaginal atrophy. Climacteric 2010;13:509-522.
47. Marsden J, Sturdee D. Cancer issues. Best Pract Res Clin Obstet Gynaecol 2009;23:87-107.
48. King J, Wynne CH, Assersohn L, Jones A. Hormone replacement therapy and women with premature menopause - a cancer survivorship issue. Eur J Cancer 2011;47:1623-1632.
49. Panjari M, Davis SR. Vaginal DHEA to treat menopause related atrophy: a review of the evidence. Maturitas 2011;70:22-25.
50. Labrie F, Cusan L, Gomez JL, Côté I, Bérubé R, Bélanger P, Martel C, Labrie C. Effect of intravaginal DHEA on serum DHEA and eleven of its metabolites in postmenopausal women. J Steroid Biochem Mol Biol 2008;111:178-194.
51. Labrie F. DHEA, important source of sex steroids in men and even more in women. Prog Brain Res 2010;182:97-148.
52. Labrie F, Archer D, Bouchard C, Fortier M, Cusan L, Gomez JL, Girard G, et al. Effect of intravaginal dehydroepiandrosterone (Prasterone) on libido and sexual dysfunction in postmenopausal women. Menopause 2009;16:923-931.
53. Key T, Appleby P, Barnes I, Reeves G; Endogenous Hormones and Breast Cancer Collaborative Group. Endogenous sex hormones and breast cancer in postmenopausal women: reanalysis of nine prospective studies. J Natl Cancer Inst 2002;94:606-616.
54. Melisko M, Rugo H, DeLuca A, Park J, Moasser M, Munster P, Goldman M, et al. A Phase II study of vaginal testosterone cream vs. estring for vaginal dryness or decreased libido in women with early stage breast cancer treated with aromatase inhibitors. Cancer Res 2009;69:[Abstract nr 5038].
55. Witherby S, Johnson J, Demers L, Mount S, Littenberg B, Maclean CD, Wood M, Muss H. Topical testosterone for breast cancer patients with vaginal atrophy related to aromatase inhibitors: a phase I/II study. Oncologist 2011;16:424-431.
56. Estrogen and progestogen use in postmenopausal women: 2010 position statement of The North American Menopause Society. Position Statement. Menopause 2010;17:242-255.